A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 14, 2021

Primary Completion Date

August 2, 2022

Study Completion Date

December 19, 2022

Conditions
Anthrax
Interventions
BIOLOGICAL

GC1109 or Placebo of GC1109

"Step1: Administer 0.3mL or 0.5mL or 0.1mL or placebo of GC1109 into the deltoid muscle three times every four weeks.~Step2: Administer 1.0mL of GC1109 or placebo of GC1109 into the deltoid muscle three times every four weeks, and once after 24 weeks."

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Korean Center for Disease Control and Prevention

OTHER_GOV

lead

Green Cross Corporation

INDUSTRY